Starpharma Pty Limited

Baker Idi Heart and Diabetes Institute Holdings Limited

Zemin Wu

Guy Yeoman Krippner

Brian Devlin Kelly

Pasquale Razzino

Benjamin James Boyd

Peter Karellas

Lisa Michelle Kaminskas

Christopher John Hamilton Porter

Sue Pallich

Karlheinz Peter

David James Owen

Scott Andrew Henderson

Charlotte Claire Williams

Christoph Hagemeyer

Christopher John Porter

The present invention relates generally to branched macromolecules and their use as imaging or contrast agents. In particular, the invention relates to dendrimers, derived from lysine or lysine analogs, bearing a plurality of functional moieties and their application to imaging techniques in which a disease state may be imaged with a targeted contrast agent.

Polylysine dendrimer contrast agent

The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups.

Modified macromolecule

The present invention relates generally to branched macromolecules bearing functional moieties. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties. The invention further relates to the use of such macromolecules, particularly in therapeutic applications, and compositions comprising them.

Targeted polylysine dendrimer therapeutic agent

Growing community of inventors

Doncaster East, Australia

Zemin Wu